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Clostridium diﬃcile colitis, although rare, could represent a serious complication following chemotherapy. Prior antibiotic use
has been considered the single most important risk factor in the development of C. diﬃcile infection. Recently, the association




days. We describe the second case reported of a patient developing a severe C. diﬃcile colitis following chemotherapy without any
recent antibiotic use and review the data of the literature, emphasizing the need to a prompt diagnosis and management that can
signiﬁcantly decrease the morbidity and life-threatening complications associated with this infection.
1.Introduction
Combination chemotherapy regimens including paclitaxel
have been widely used for standard treatment of many
solid tumors, including ovarian cancer [1]. Recently, a
range of acute serious gastrointestinal complications such as
necrotizing colonic inﬂammatory disorders, pancolitis, and
ischemic colitis have been reported in paclitaxel containing
regimens [2–6].
The association between cancer chemotherapy and
Clostridium diﬃcile-associated colitis has recently become
more apparent; however, the exact mechanism is poorly
understood. Prior antibiotic therapy is considered the single
most important risk factor in the development of C. diﬃcile-
associated diarrhea. Nevertheless, few cases of patients
aﬀected by severe C. diﬃcile colitis following chemotherapy
in the absence of recent antibiotic use have recently been
reported [7, 8].
Here, we describe a case of a woman with advanced
ovarian carcinoma who developed severe pancolitis caused
by C. diﬃcile after ﬁve cycles of paclitaxel and carboplatin
chemotherapy without any recent antibiotic use. Moreover,
we reviewed the literature concerning the management
and treatment of patients with severe C. diﬃcile infec-
tion.
2.CaseReport
In September 2007, a 75-year-old Caucasian woman with
stage IIIB papillary serous ovarian adenocarcinoma was
admitted in the Division of Gynecologic Oncology of
the Catholic University. She underwent an explorative
laparoscopy, for a pelvic mass, diﬀuse peritoneal carcino-
matosis, and ascites. Within two weeks the patient received
the ﬁrst cycle of Paclitaxel (135mg/m2) and Carboplatin
(AUC 4). The ﬁrst four cycles were well tolerated, showing
no major hematologic or organ toxicity with complete
response to chemotherapy. Therefore, she underwent opti-
mal cytoreductive surgery with no residual disease left in the
pelvis and the upper abdomen. One month after surgery,2 Obstetrics and Gynecology International
Figure 1: A CT-scan of the abdomen showing increased thickness
of the colonic wall.
the patient received her ﬁfth cycle of chemotherapy. The
day after the administration of chemotherapy, she reported
abdominal pain, fever (101, 3◦F), and asthenia, and after
4 days. She presented diarrhea, coﬀee-ground emesis, and
oligoanuria.
Hematologic laboratory values were haemoglobin (g/dl)
8, 9, white blood cell count 4.70 × 109/l. Physical exami-
nation revealed a diﬀuse abdominal tenderness, distension,
and guarding. A CT-scan (Figure 1)r e v e a l e da ni n c r e a s e d
thickness of colonic wall compatible with diﬀuse severe
pancolitis. White blood cell count was 1.39 × 109/l. Patient’s
blood cultures were negative. Assay of stool specimens
revealed Clostridium diﬃcile toxin. The patient’s sepsis was
treated with intravenous metronidazole (500gr i.v, 4 times
ad a y ) ,β-lactamic antibiotic (1gr i.v, 3 times a day), and
teicoplanin (600mg i.v). Oral vancomycin (500mg 4 times a
day) was also administered by nasogastric tube. The patient’s
condition worsened, and after 7 days of therapy she was
transferred in the Intensive Care Unit of our hospital.
At a day twenty following admission for chemotherapy,
she died.
3. Discussion
The mechanism of colitis as a complication of taxane-based
chemotherapy is still unknown [9, 10]. Paclitaxel, as well as
docetaxel, binds to the β subunit of tubulin, which results in
the formation of stable, nonfunctional microtubule bundles
that interfere with mitosis [11, 12].
C. diﬃcile is an etiologic agent for antibiotic-associated
diarrhea (15%–25% of all cases) and pseudomembranous
colitis (95%–100% of all cases) [13]. Prior antibiotic ther-
apy (in particular broad-spectrum antibiotics with activity
against enteric bacteria, such as clindamycin, but also
penicillins and cephalosporins) is considered the single most
important risk factor in the development of C. diﬃcile-
associated diarrhea. However, the association between anti-
neoplastic therapy and C. diﬃcile infection in the absence of
apriorantibiotictherapyhasrecentlybecomemoreapparent
[13]. Among patients with gynaecologic cancer and diarrhea
without associated antibiotic use, the incidence of C. diﬃcile
has been found to be 8% in ovarian cancer patients [14],
6% in cisplatin-based chemotherapy [15], 2,2% in patients
receiving standard-dose paclitaxel containing regimens and
ashighas20%inthosetreatedwithhigh-doseregimens[16].
Carboplatinhasbeenreportedtohavelessintestinalmucosal
toxicity than cisplatin [17], and to our knowledge, only one
case of C. diﬃcile colitis induced by carboplatin used in
association with paclitaxel has been previously reported [8].
The severity of C. diﬃcile infection ranges from an asymp-
tomatic carrier status to life-threatening pancolitis. Most
commonly, C. diﬃcile colitis presents as mild to moderate
diarrhea associated with occasional abdominal cramps. As
the severity of the disease increases, systemic manifestations
include fever, leucocytosis, nausea, dehydration associated
with profuse diarrhea, and abdominal pain and distension.
Plain abdominal radiographs are usually not speciﬁc, and
the diagnosis is usually conﬁrmed by CT scan and, as the
inﬂammatory process in the colon may be localized or
diﬀuse, CT would be also useful in assessing the extent of
the colitis [18].
For patients with severe or fulminant infection whose
gastrointestinaltractsarefunctioning,oralvancomycinisthe
preferred therapy [19]. A recent double-blind randomized
cinical study by Zar et al. indicated that the clinical cure rate
for vancomycin in patients with severe CDI is signiﬁcantly
better than for metronidazole (97% versus 76%; P<. 02)
[19].
Whereas, the best treatment for patients with compro-
mised gastrointestinal tract function remains controversial
[18–26]. For these patients, delivery of reliable concentra-
tions of orally administered drug to the site of infection
cannot be assured. Some experiences support the use
of intravenous metronidazole for treatment of C. diﬃcile
diarrhea [20, 21]. However, alternative methods to ensure
eﬀective antimicrobial concentrations at the site of infection
should also be undertaken. For example, oral vancomycin
should be given in addition to intravenous metronidazole.
When severe adynamic ileus is suspected, intraluminal van-
comycinshouldbeconsidered,byalongcatheterinthesmall
intestine [22], direct intracolonic instillation [23], or rectal
delivery through an enema [23–25]. If these approaches are
unsuccessful and the patient’s clinical condition deteriorates,
subtotal colectomy with a temporary diverting ileostomy is
the only life-saving alternative [26].
The occurrence of C. diﬃcile infection in patients
undergoing chemotherapy for gynaecological cancer is not
rare and should be considered and treated promptly in
the diﬀerential diagnosis of patients presenting diarrhea.
Although the incidence of C. diﬃcile infection is more
frequentinthosepatientstreatedsimultaneouslywithantibi-
otics and chemotherapeutic agents, this is the second case
reported of a patient developing a severe C. diﬃcile colitis
following paclitaxel and carboplatin regimen without any
recent antibiotic use [8]. Aggressive supportive care with
i.v. hydratation, broad-spectrum antibiotics, and close sur-
gical monitoring for selective intervention can signiﬁcantly
decrease the morbidity and life-threatening complications
associated with this infection.Obstetrics and Gynecology International 3
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